18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Ovarian Neoplasms, Ovarian Cancer, Fallopian Tube Neoplasms
About this trial
This is an interventional diagnostic trial for Ovarian Neoplasms focused on measuring Apoptosis, Pro-Apoptotic Effects, PET Imaging, TL32711, Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer
Eligibility Criteria
- INCLUSION CRITERIA
Subjects with pathology proven epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer that are relapsed or refractory to prior platinum-based standard care systemic regimen, enrolled, or eligible to be enrolled in the Phase 2 NCI protocol treatment using Birinapant (NCI Protocol (#12C0191)CTEP 9235); therefore must meet the inclusion criteria for that study
Ability to provide informed consent. All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of this study before any protocol related studies are performed.
EXCLUSION CRITERIA
Known allergy to any of the formulation components of [18F]-CP18.
The subject is pregnant or nursing
Participants for whom enrollment would significantly delay (> 2 weeks) the scheduled standard of care therapy.
Participants with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results are excluded.
Participants with severe claustrophobia not relieved by oral anxiolytic medication or patients weighing >136 kg (weight limit for scanner table).
Other medical conditions deemed by the PI or associates to make the patient ineligible for protocol procedures.
It is likely that all patients in this study will be surgically sterile. If this is not the case, the patient must have a negative serum beta HCG within 24 hour prior to PET/CT or be post-menopausal for greater than or equal to 2 years